Cytokines and growth factors use specific receptor-associated tyrosine kinases to initiate intracellular signaling cascades. Although growth factors such as epidermal growth factor interact with cell-surface receptors possessing intrinsic tyrosine kinase domains, the majority of cytokines use receptors that lack this but instead associate with a family of exogenous kinases called JAKs 1,2 . Cytokine binding to these receptors allows JAK dimers to self-activate, in trans, from an inactive state, and this initiates the signaling cascade 3,4 . To prevent aberrant or prolonged signaling that could lead to pathological proliferation and carcinogenesis, there is a need for these receptor-associated kinases to be regulated tightly.
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Cytokines and growth factors use specific receptor-associated tyrosine kinases to initiate intracellular signaling cascades. Although growth factors such as epidermal growth factor interact with cell-surface receptors possessing intrinsic tyrosine kinase domains, the majority of cytokines use receptors that lack this but instead associate with a family of exogenous kinases called JAKs 1, 2 . Cytokine binding to these receptors allows JAK dimers to self-activate, in trans, from an inactive state, and this initiates the signaling cascade 3, 4 . To prevent aberrant or prolonged signaling that could lead to pathological proliferation and carcinogenesis, there is a need for these receptor-associated kinases to be regulated tightly.
The principal regulators of JAK-STAT signaling are the suppressor of cytokine signaling (SOCS) family of proteins [5] [6] [7] [8] . The human genome encodes eight SOCS proteins (SOCS1-7 and CIS), and all share a similar architecture that includes a central SH2 domain followed by a SOCS-box domain at their C termini. The SH2 domain recruits tyrosine-phosphorylated substrates, whereas the SOCS box binds elongins B and C and cullin 5, which leads to the ubiquitination of these substrates [9] [10] [11] [12] [13] . Thus SOCS proteins can be considered to be the substrate-recruitment modules of E3 ubiquitin ligases that act to shut down cytokine signaling by inducing the proteolytic degradation of signaling molecules.
The two most potent members of the family, SOCS1 and SOCS3, act through an additional mechanism. They contain a short motif, termed the kinase-inhibitory region (KIR), that allows them to suppress signaling by direct inhibition of JAK catalytic activity 14, 15 . This is the primary mode of action of SOCS1 and SOCS3, as deletion of their SOCS-box domain alone (and hence elimination of ubiquitination activity) results in a much milder phenotype 12, 16 than does full knockout.
There are four mammalian JAKs (JAK1-3 and TYK2). Recently, it has been shown that SOCS3 directly inhibits JAK1, JAK2 and TYK2 but does not inhibit JAK3 (ref. 17) . Despite the ability of SOCS3 to inhibit these JAKs, deletion of SOCS3 in mice has revealed specificity for particular cytokines, including leukemia inhibitory factor (LIF) 18 and interleukin-6 (IL-6) 19 (which both signal through the IL-6 receptor β chain, gp130) as well as granulocyte colony-stimulating factor (G-CSF) 20 and leptin 21 . Specificity arises from the ability of SOCS3 to inhibit only JAKs associated with certain cytokine receptors. The gp130, LIF and leptin receptors all contain phosphotyrosine motifs that act as SOCS3-binding sites [22] [23] [24] . Whether these motifs act to bring SOCS3 into proximity with JAK before it shuttles off the receptor to bind JAK directly, or whether SOCS3 can bind both JAK and receptor simultaneously has been unclear.
To determine the molecular mechanism of SOCS3 action, we solved the crystal structure of a SOCS3-JAK2-gp130 complex, which showed that SOCS3 is bound to both the kinase domain of JAK2 and a fragment of the IL-6 receptor (gp130) at the same time. The gp130 fragment resides in the canonical phosphotyrosinebinding groove of SOCS3, whereas a surface on the other face of the SH2 domain is used to anchor JAK2. Given that in vivo JAK is also bound to gp130, the structure indicated that the true (high affinity) target of SOCS3 is a JAK-gp130 complex rather than JAK or gp130 alone. This explains why SOCS3 is highly specific for IL-6-family cytokines and others, such as G-CSF, whose receptors also contain SOCS3-binding motifs. Structural and biochemical analysis also revealed that the KIR of SOCS3 occupies the substratebinding groove on JAK2 and occludes the P+1 pocket (the pocket in which the residue adjacent to a substrate tyrosine resides).
The arginine immediately upstream of the KIR acts as the pseudosubstrate residue, which indicates that SOCS3 inhibits signaling by blocking the substrate-binding site of the kinase that initiates the intracellular signaling cascade.
RESULTS

SOCS3 binds JAK and cytokine receptor simultaneously
To determine the molecular details of a SOCS3-JAK2-receptor interaction, we solved the crystal structure of a SOCS3-JAK2-gp130 ternary complex (SOCS3 22-185 -JAK2 JH1 -gp130 750-764 ; Fig. 1a) . SOCS3 was used, as previous work had defined it as the minimal fully active fragment 14 , and full-length SOCS3 is poorly soluble. The gp130 shared co-receptor contains a single SOCS3-binding site, centered on pTyr757 (ref. 24) . As the full intracellular domain of the receptor is over 250 residues in length and unstructured 25 , we prepared a phosphorylated fragment of this receptor (gp130 750-764 : STASTVEpYSTVVHSG). The crystal structure of this peptide in complex with SOCS3 has been solved previously 26 . Finally, the tyrosine kinase (JH1) domain of JAK2 (JAK2 JH1 ) was used, as it contains the SOCS3-interaction site 17 . An ATP mimetic was necessary to successfully crystallize JAK2 JH1 previously 27 , and therefore a stoichiometric equivalent of CMP-6 was added to several of our crystallization trials.
Small crystals of a 1:1:1 (SOCS3-JAK2-gp130) complex were obtained, the best of which diffracted to 3.9 Å. Phasing was achieved by molecular replacement using the higher-resolution JAK2 (PDB: 3FUP) and SOCS3 structures (PDB: 2HMH). The structure was refined to R work and R free values of 0.2491 and 0.2808, respectively ( Table 1) . Despite this relatively low resolution, the fundamental details of the JAK2-SOCS3-gp130 interaction are clear.
It was unclear whether SOCS3 would remain bound to the gp130 fragment in the presence of JAK2. After initial rounds of refinement, clear difference density in F o -F c maps for the gp130 fragment could be observed in the canonical phosphotyrosine (pTyr) binding groove on the SH2 domain of SOCS3 (Fig. 1b and Supplementary Fig. 1 ). The gp130 fragment lies across the central three-stranded β-sheet of the SH2 domain with the phosphotyrosine coordinated by the conserved Arg71 in βB, the serines in the BC loop and Arg94 in βD (Fig. 1c) , just as seen in the absence of JAK2 (ref. 26) .
The SOCS3 BC loop that helps coordinate the pTyr also contacts JAK2 (Fig. 1d) . In fact, gp130 pTyr757 is located within 7 Å of JAK2 at its closest point. To investigate whether binding of JAK2 influences the binding of gp130 or vice versa, we attempted to determine the structure of a SOCS3-JAK2 complex in the absence of gp130. However, crystals obtained only diffracted to 7 Å. Although this resolution is too low for structure determination, these SOCS3-JAK2 crystals grew in the same conditions as did SOCS3-JAK2-gp130 and had essentially identical cell dimensions, which suggests that gp130 does not induce any large conformational changes.
SOCS3 binding is centered on the GQM motif
We observed four SOCS3-JAK2-gp130 trimers in the asymmetric unit and two potential SOCS3-JAK2 interfaces. The interface with the higher buried surface area (980 compared to 660 Å 2 ) mapped to the region of SOCS3 identified by NMR to bind JAK2 and was consistent with mutagenesis data 17 .
Further support for this assembly being representative of the biologically functional complex in solution was obtained by using small-angle X-ray scattering (SAXS). The SOCS3-JAK2-gp130 complex crystal structure is consistent with an ab initio bead model calculated from experimental scattering data (Fig. 1e) . In addition, the theoretical scattering curve calculated for the crystal structure is in agreement with the experimental scattering curve (Supplementary Fig. 2 ; χ = 0.658 for fit). SAXS data-collection statistics are presented in Supplementary Table 1 .
The SOCS3-JAK2 interface is predominantly hydrophobic and is centered upon the GQM motif 17 in JAK2. This short motif (residues Gly1071, Gln1072 and Met1073 of JAK2) is responsible for the ability of SOCS3 to selectively bind JAK1, JAK2 and TYK2 but not JAK3, and it sits at the junction of the 'JAK Within the GQM motif, Gln1072 and Met1073 are buried deeply at the interface with SOCS3 (Fig. 2a,b) . Gln1072 is stacked against the conserved SOCS3 residue Phe79, whereas Met1073 sits in a hydrophobic pocket formed by the SOCS3 ESS helix and two adjacent phenylalanines on the BC loop (Phe79-Phe80). Gly1071 allows the BC loop of SOCS3 to stack against the peptide backbone of JAK2 and provides the torsional flexibility for a tight turn immediately preceding the αG helix. Mutation of either Gly1071 or Met1073 renders JAK2 resistant to inhibition by SOCS3 (ref. 17) . The interface extends out from the GQM motif into the αG helix of JAK2 where Met1073 and Phe1076 form a nonpolar surface that packs against a hydrophobic surface on SOCS3. It appears that the adjacent Asp1080 on the third turn of this helix in JAK2 forms a hydrogen bond with Tyr31 on SOCS3; however, the electron density for that side chain is not resolved well enough to state this unequivocally. Only minor conformational changes in the JAK2 GQM motif can be seen upon binding SOCS3. In contrast, this region adopts a very different orientation in JAK3, which lacks a GQM motif (Supplementary Fig. 3 ).
The JAK2-binding site on SOCS3
The SOCS3-JAK2-gp130 structure revealed that the majority of the JAK2-binding surface on SOCS3 is a concave hydrophobic region formed by the ESS and the BC loop. This loop is responsible for coordinating pTyr757 from gp130 (ref. 26) , and its opposite face contacts JAK2. In particular, Asp72, Ser73, Phe79 and Phe80 from this loop all contact JAK2 directly. The SOCS3 ESS is an amphipathic α-helix, and the hydrophobic face of this helix contacts residues from the similarly hydrophobic face of JAK2 αG. JAK2 binding induces an extra helical turn at the beginning of the ESS helix, and the whole region undergoes a translation of half a helical turn (Fig. 2c) . This reconfiguration leads to a slightly larger hydrophobic face than in the absence of JAK2. 
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The key feature of the JAK2-binding site involves the SOCS3 KIR. The eight-residue KIR lies immediately upstream of the ESS (Fig. 2d) and is unstructured in isolation 26, 29 . However, in our complex structure it was sharply folded back underneath the BC loop with its three N-terminal residues (Leu22-Thr24) occupying a deep groove on the JAK2 surface ( Fig. 3a and Supplementary Fig. 4 ). Although these contribute few intermolecular hydrogen bonds, there are many van der Waals contacts, which make up over 20% of the total buried surface area within the complex. Within the KIR, Phe25 is particularly important, as it is placed in a deep hydrophobic pocket at the interface of the two proteins that is formed by residues from both SOCS3 and JAK2, and this residue is known to be required for SOCS inhibitory activity 14 . Collectively, the KIR and residues from the ESS and the BC loop of the SH2 domain form the JAK binding site.
To fully characterize this site, an alanine scan was performed on SOCS3 residues that contact JAK2, and the ability of these mutants to inhibit JAK2 was tested. Three residues were found to be essential: Phe25 from the KIR and Phe79 and Phe80 from the BC loop ( Table 2 and Fig. 3b) . These are absolutely conserved in SOCS3 and SOCS1 in all vertebrates. Of the remaining residues, mutation of Glu30 resulted in a 20-fold increase in the half-maximum inhibitory concentration (IC 50 ), possibly because it helps to position the SOCS3 KIR at 90° to the ESS helix by hydrogen-bonding with Ser26. Mutation of Tyr47 impaired activity; however it hydrogen-bonds with Asp72, and this pair of residues is conserved across all SOCS proteins, even those that do not bind JAK2, and they are likely to have a structural role within the SH2 domain.
To further characterize the KIR, we investigated whether, on its own, it was capable of inhibiting JAK2. The SOCS3 KIR as an isolated peptide could not inhibit the kinase activity of JAK2. However, the KIR of SOCS1 (the only other SOCS protein known to directly inhibit JAK2 (ref. 15)) inhibited JAK2, albeit with low (100 µM) affinity (Fig. 3c) . Although the sequence identity between SOCS1 and SOCS3 is only 33%, the SOCS-JAK interface site is almost completely conserved (Fig. 3d,e) . This suggests that SOCS1 will share the same mode of interaction with JAK2 as does SOCS3.
The kinase-inhibitory region is required for JAK binding
The failure of the F25A KIR mutant to inhibit JAK2 indicates that the KIR is required for inhibition but does not necessarily indicate that it is required for binding to JAK2. To investigate this, a series of mutants with truncated KIRs was constructed, and co-precipitation experiments were employed. The concentration of JAK2 used in each pulldown was 5 µM with a two-fold molar excess of SOCS3-elonginBC. The elonginBC complex is the physiological ligand for the SOCS box of SOCS proteins and increases their solubility. The K d of the SOCS3-JAK2 interaction is approximately 1 µM 30 , and these concentrations were chosen to ensure that a near-stoichiometric (85%) pulldown of SOCS3 would occur for the wild-type construct, whereas an increase in the K d of >5-fold for the mutant constructs should lead to a visible reduction in the pulldown efficiency. There was a gradual loss of JAK2 binding as residues were removed, with SOCS3 ∆N24 , which begins at Phe25, showing no detectable interaction with JAK2 (Fig. 4a) .
The importance of Phe25 is demonstrated by the abolition of the interaction between JAK2 and SOCS3 by mutation of this residue to alanine. To date, there has been an assumption that SOCS3 would npg a r t i c l e s bind directly to JAK2 pTyr1007 or pTyr1008 through its SH2 domain as part of its inhibitory mechanism, even if it was not the sole site of binding. However, our crystal structure showed no contact between SOCS3 and pTyr1007 or pTyr1008, and SOCS3 bound dephosphorylated JAK2 (JAK2 Tyr1007 Tyr1008 ) with similar affinity to phosphorylated JAK2 (JAK2 pTyr1007 pTyr1008 ) ( Fig. 4b and Supplementary  Fig. 5 ). Moreover, there was no binding to JAK2 when the JAK2 GQM motif was mutated (G1071D; Fig. 4c) , even though the activation loop was phosphorylated, as determined by western blotting with a pTyr1007-specific antibody (data not shown).
SOCS3 inhibits JAK2 by blocking substrate binding
The substrate-binding site of JAK2 can be modeled by using the insulin receptor kinase (IRK)-insulin receptor substrate-1 complex (PDB: 1IR3) 31 . This indicated that the KIR of SOCS3 partially occupies the substrate-binding groove (Fig. 5a) . In particular, the first residue of the KIR, Leu22, sits in the predicted P+1 binding site, one residue downstream from the substrate tyrosine. Therefore, we hypothesized that SOCS3 inhibits JAK2 by blocking substrate binding. However, given that our previous work had shown that SOCS3 displayed apparently noncompetitive inhibition kinetics regarding substrate 17 , this hypothesis required further validation. We reasoned that if the SOCS3 KIR functions by blocking substrate binding, then truncating one or more residues from its N-terminal end (Fig. 5b) would reduce the ability of SOCS3 to inhibit JAK2. SOCS3 mutants that lacked the first one to three residues of the KIR showed quantitative and qualitative differences when compared to wild-type SOCS3 ( Fig. 5c and Supplementary Fig. 6 ). Deleting the first one or two residues led to a ten-fold increase in the IC 50 , whereas deleting the third residue increased this by a further ten-fold. Owing to the high concentrations of SOCS3 proteins used in these assays, inhibition could be observed even for SOCS3 ∆N24 . Changes in IC 50 indicate changes in the affinity of the interaction. Of greater interest was the fact that these shorter constructs could not achieve 100% inhibition of JAK, even at saturating concentrations. For example, when JAK2 was fully bound by SOCS3 ∆N22 and SOCS3 ∆N23 , it retained 25% of its activity. These data are consistent with a model in which these truncated forms of SOCS3 cannot completely block substrate binding because of the reduced overlap between the N terminus of the KIR and the substrate. For example, a reduction in the affinity of substrate for a SOCS3 ∆N22 -JAK2 complex (compared to its affinity for JAK2 alone) would lead to the observed residual activity. In contrast, the affinity of substrate for a SOCS3 ∆N21 -JAK2 Figure 4 The KIR is required for JAK binding. npg a r t i c l e s complex is zero, as the binding site is completely blocked. In support of this, we found that when this overlap was reduced even further by using a C-terminally truncated form of the substrate, which only contained a single residue downstream of the tyrosine, inhibition was even less complete (50%; Fig. 5c ).
Residues upstream of the KIR can act as a pseudosubstrate
One characteristic of substrate-blocking inhibitors is that they act as pseudosubstrates. The SOCS3-JAK2-gp130 structure showed that the first residue of the SOCS3 KIR, Leu22, sits in the P+1 binding site, not in the tyrosine-binding site itself. This suggested that a residue upstream of the KIR, rather than any residue within it, would be the true pseudosubstrate residue.
To determine whether this is the case, we constructed various mutant forms of SOCS3, with a tyrosine residue one to six residues upstream of Leu22. Glycine was used as the spacer residue(s) between the tyrosine and Leu22. A SOCS3 mutant containing tyrosine at position 22 (L22Y) was present as a negative control because, on the basis of our structure, it should not be phosphorylated. Tyrosines at positions 21, 20 and 19 of SOCS3 were very efficiently phosphorylated by JAK2 ( Fig. 6a and Supplementary Fig. 6b ). This efficiency is because they are bound in a specific orientation on JAK2, which localizes them to the active site, as F25A versions of these mutants were not phosphorylated to the same extent (Fig. 6b) .
For solubility reasons, all our biochemical and structural studies to date have used constructs of SOCS3 beginning at residue 22, the N terminus of the KIR, rather than at residue 1. Given that residue 21 is the true pseudosubstrate residue, we were concerned that the SOCS3 KIR may have been misdefined as only consisting of residues 22 onward and that full-length SOCS3 may be a more potent inhibitor and perhaps display competitive kinetics. Therefore, we purified full-length SOCS3 and performed a full steady-state kinetic analysis. SOCS3 1-225 inhibited JAK2 with an identical IC 50 to SOCS3 and was also apparently noncompetitive regarding substrate (Fig. 6c,d) . These results combined with previous cellular data 14, 32 suggest that there are no experiments that can distinguish between full-length SOCS3 and SOCS3 lacking the first 21 residues.
That JAK2 is active when bound by SOCS3 further supports the hypothesis that SOCS3 functions by blocking substrate binding and not by preventing catalysis per se. These data, in addition to the correlation between the degree of overlap between SOCS3 and the substrate and the degree of inhibition (Fig. 5) , as well as the structure of the SOCS3-JAK2-gp130 complex, lead us to conclude that SOCS3 inhibits JAK2 by blocking substrate binding. 14 and yet, in a biological context, shows remarkable specificity for inhibiting JAK signaling only when stimulated by particular cytokines. The SOCS3-JAK2-gp130 structure, along with supporting biochemical data, elucidates the mechanism of SOCS3 inhibition and provides the molecular basis of its specificity. In short, SOCS3 inhibits JAK's enzymatic activity by blocking substrate binding and gains specificity of action by only binding tightly to JAK when the kinase is attached to specific receptors.
DISCUSSION
SOCS3 is a potent inhibitor of JAK
Given that our previous data had shown that SOCS3 inhibits JAK2 with noncompetitive kinetics toward substrate 17 , the above model required further validation. We reasoned that there were two testable aspects to the hypothesis: (i) if SOCS3 blocks substrate binding using the KIR, then truncating this region should lead to impaired inhibition, and (ii) if SOCS3 acts as a pseudosubstrate, then it should be convertible to a substrate by mutating the appropriate residue to tyrosine. The outcome of both of these experiments supports our model; even under saturating SOCS3 concentrations, truncation of the KIR led to impaired inhibition, and mutating residues 19-21 to tyrosines converted SOCS3 into a high-affinity JAK2 substrate.
That tyrosines placed in three consecutive positions were equally good substrates was unexpected. There are two major interactions that exist between a tyrosine kinase and a substrate tyrosine: the tyrosine ring stacks on a conserved proline (Pro1017 in JAK2), and a hydrogen bond forms between the tyrosine hydroxyl and the catalytic aspartate (Asp976 in JAK2). It is unlikely that the tyrosine-proline interaction could occur for all three of our mutants, but there may be enough flexibility in the main chain and tyrosine side chain χ1 torsion angle to allow the tyrosine-aspartate hydrogen bond. If the tyrosine-proline interaction is not essential, then other hydroxyl-containing residues might act as substrates when forced near the JAK active site. Indeed, we observed that a threonine placed at position 19 of SOCS3 was also phosphorylated (Supplementary Fig. 7) .
Although tyrosines at positions 19, 20 or 21 were equally good substrates, our structure suggests that residue 21 is the true npg a r t i c l e s pseudosubstrate residue. This residue in SOCS3 and SOCS1 is conserved throughout evolution as an arginine or histidine. Modeling these into our structure suggests that both of these are long enough to hydrogen-bond with Asp976, and they contain a planar element on their side chains that could stack onto Pro1017. However, Arg21 does not seem to provide any extra affinity toward JAK2 and is not required for complete inhibition. Therefore, any interactions it makes seem to be dispensable regarding SOCS3 function. A previous study has described several mechanisms through which active site-binding molecules can display apparently noncompetitive kinetics 33 . The two that appear most plausible here are either that SOCS3 binding blocks ADP release or that there is a slow step in SOCS3 binding to JAK2 that breaks the rapid-equilibrium assumption. In the latter case, for example, SOCS3 may form a rapid encounter complex with JAK2 within milliseconds, followed by a slower reorientation (within seconds) of the SOCS3 KIR into the substratebinding groove. The initial encounter complex would not involve the KIR and hence would not compete with substrate binding. Either of these scenarios could explain the kinetic data.
The structure of the SOCS3-JAK2-gp130 complex demonstrates explicitly that SOCS3 binds JAK2 and cytokine receptor simultaneously. This has important functional consequences, as it allows for the formation of an unusual ternary complex (JAK-SOCS-receptor) in which each moiety is bound directly to the other two. Such a complex will show an overall stability (affinity) that is much greater than the sum of its individual interactions. In effect, although SOCS3 binds JAK2 with micromolar affinity, it will bind a JAK2-receptor complex with much higher affinity, provided that the receptor has a SOCS3-interaction motif. Genetic deletion of SOCS3 has shown it to be a critical inhibitor of LIF, G-CSF, leptin and IL-6, and all of these cytokines act through receptors with a known SOCS3-interaction motif. Our data predict that if the concentration of SOCS3 in the cytoplasm is high enough (that is, approaching 1 µM, the K d of the SOCS3-JAK2 interaction), it will circumvent the need for receptor-mediated JAK binding, and SOCS3 will bind and inhibit all of JAK1, JAK2 and TYK2. This is supported by the fact that SOCS3 is known to inhibit a multitude of different cytokines when artificially overexpressed (reviewed in ref. 34) . Notably, our model of SOCS3 action and specificity does not require it to be bound to the same receptor chain as JAK2, as the opposing chain(s) in a receptor dimer or oligomer would also induce the same high-affinity ternary complex.
The SOCS3-JAK2-gp130 structure reveals many parallels between SOCS3 inhibition of JAK signaling and Grb14 inhibition of the insulin receptor tyrosine kinase (Fig. 7) . Grb14 is anchored to the IRK domain by its SH2 domain, and it blocks substrate binding through a KIR-like region N terminal to this. The KIR-like motif in Grb14 is unstructured in the absence of IRK in the same way that the SOCS3 KIR is unstructured in the absence of JAK 35 . Finally, Grb14 also acts as a pseudosubstrate without displaying competitive kinetics 36, 37 . The major difference between Grb14 and SOCS3 is that the former anchors itself to IRK by binding its phosphorylated activation loop through the canonical phosphotyrosine binding groove, whereas SOCS3 binds JAK2 by a noncanonical surface that frees the phosphotyrosine-binding groove to bind receptor. Notably, the SOCS3-JAK2 interaction does not involve phosphotyrosines on the activation loop of JAK2 as previously supposed 15 but instead is mediated by a hydrophobic surface on JAK2. Overall, this surface is very similar to that used by the inhibitory-switch region of PAK1 (ref. 38 ). However, autoinhibition of PAK1 disrupts the catalytic site, whereas SOCS3 and Grb14 act by blocking substrate. Although there is a relatively long (23-residue) flexible linker between the SH2 domain of Grb14 and its KIR-like region, in SOCS3 the two are attached by a short, rigid, helical linker (the ESS), which is probably necessary to ensure that the KIR remains tightly bound to the substrate-binding groove (given that the KIR on its own has a relatively low affinity for JAK2). Therefore, in SOCS3, the SH2 domain both tethers and positions the KIR for binding, whereas in Grb14 it merely tethers.
Activating mutations in JAK2, particularly V617F, are associated with the majority of cases of myeloproliferative neoplasms such as polycythemia vera 39 and are also found in a number of acute leukemias 40 . As such, JAK2 has long been recognized as an important drug target for the treatment of a number of hematological malignancies, and currently there are at least six different JAK inhibitors in clinical trials for myeloid disease 41 . All of these trials are using compounds that bind the ATP-binding site of JAK2 and are therefore ATP competitive. Such compounds are outcompeted by high intracellular ATP concentrations and are prone to off-target effects, as their site of interaction is structurally similar throughout the kinome. SOCS3, by virtue of being noncompetitive toward ATP, is unaffected by the high concentration of ATP within the cytoplasm and targets only JAK1, JAK2 and TYK2. The structural details presented here provide information that could be used in the development of a small-molecule mimetic of the SOCS3 KIR, which would offer distinct advantages over all currently available JAK-targeted therapeutics. 
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Although the structure presented here is of a specific SOCS (SOCS3) bound to a specific JAK (JAK2) and receptor (gp130), it has wider significance in terms of SOCS-JAK-receptor biology. It seems clear that SOCS3 will bind the same surface on JAK1 and TYK2 as it does on JAK2 (ref. 17) , and given the sequence similarity between SOCS1 and SOCS3, especially in the JAK-binding surface, we believe that SOCS1 will interact in the same way with these three JAKs. Because all cytokines that signal through the JAK-STAT pathway use at least one of these three kinases, the structure presented here provides the molecular mechanism for all SOCS1-and SOCS3-based signaling inhibition. The specificity within the SOCS1,3-JAK-receptor system is provided by the receptor, and therefore it is important that the full repertoire of SOCS1-and SOCS3-binding sites on these receptors be identified. Our current efforts lie in this direction.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The atomic coordinates of the SOCS3-JAK2-gp130-CMP6 complex have been deposited in the Protein Data Bank, with accession code 4GL9.
